The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

Medical and Scientific Affairs, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD, 20878, USA, .
European Journal of Clinical Microbiology (Impact Factor: 3.02). 03/2012; 31(10):2549-57. DOI: 10.1007/s10096-012-1595-9
Source: PubMed

ABSTRACT In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing from two randomized, multinational trials of LAIV and TIV (N = 1,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p < 0.05). Relative efficacies were consistent with the results observed in the overall study populations, which demonstrated fewer cases of culture-confirmed influenza illness in LAIV compared with TIV recipients. Study results support the safety and efficacy of LAIV among children aged 2-17 years with mild to moderate asthma or a history of wheezing. Data regarding LAIV use are limited among individuals with severe asthma or active wheezing within the 7 days before vaccination.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut haben das Ziel, Infektionskrankheiten und damit assoziierte Komplikationen, die für das öffentliche Gesundheitswesen von Bedeutung (,,von öffentlichem Interesse“) sind, durch populationsbezogene Impfprogramme zu verhindern. Darüber hinaus enthalten die STIKO-Empfehlungen Hinweise für Indikationsimpfungen bei besonderer Gefährdungslage und umfassende Informationen zur Durchführung von Nachholimpfungen. Im vorliegenden Beitrag werden die Grundlagen der Impfpraxis sowie die aktuellen Empfehlungen der STIKO mit den wichtigsten Neuerungen beschrieben.
    Monatsschrift Kinderheilkunde 06/2013; 161(12). DOI:10.1007/s00112-013-2919-2 · 0.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Given the burden of illness associated with influenza, vaccination is recommended for individuals at high risk of complications. The live-attenuated influenza vaccine (LAIV) is administered by intranasal spray, thus directly stimulating mucosal immunity. In this review, we aimed to provide evidence for its efficacy and safety in different paediatric populations. We also share the Quebec experience of LAIV use through a publicly funded vaccination program for children with chronic, high-risk conditions. Results from randomized controlled trials in healthy children and in asthmatics have demonstrated superior efficacy of LAIV over the injectable vaccine (IIV). LAIV is well tolerated: its administration is associated with runny nose and nasal congestion, but not with asthma exacerbations and is well tolerated in children with cystic fibrosis, when compared to IIV. The vaccine is well accepted by children and parents and can easily be part of vaccination clinics in paediatric tertiary care centres targeting children with chronic, high-risk conditions, not leading to immunosuppression.
    Paediatric respiratory reviews 06/2014; 15(4). DOI:10.1016/j.prrv.2014.06.002 · 2.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Influenza is a worldwide prevalent infectious disease of the respiratory tract annually causing high morbidity and mortality in Germany. Influenza is preventable by vaccination and this vaccination is so far recommended by the The German Standing Committee on Vaccination (STIKO) as a standard vaccination for people from the age of 60 onwards. Up to date a parenterally administered trivalent inactivated vaccine (TIV) has been in use almost exclusively. Since 2011 however a live-attenuated vaccine (LAIV) has been approved additionally. Consecutively, since 2013 the STIKO recommends LAIV (besides TIV) for children from 2 to 17 years of age, within the scope of vaccination by specified indications. LAIV should be preferred administered in children from 2 to 6 of age. The objective of this Health Technology Assessment (HTA) is to address various research issues regarding the vaccination of children with LAIV. The analysis was performed from a medical, epidemiological and health economic perspective, as well as from an ethical, social and legal point of view.

Full-text (3 Sources)

Available from
May 31, 2014